Interaction between bevacizumab and murine VEGF-A: a reassessment.
暂无分享,去创建一个
Claudio Campa | Zhiyong Cheng | Napoleone Ferrara | G. Fuh | N. Ferrara | H. Lowman | Zhiyong Cheng | J. Lecouter | C. V. Lee | Xiumin Wu | C. Campa | Henry Lowman | Lanlan Yu | Xiumin Wu | Chingwei V. Lee | Jennifer LeCouter | Germaine Fuh | Lanlan Yu
[1] G. Fuh,et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.
[2] P. Campochiaro,et al. VEGF‐TRAPR1R2 suppresses choroidal neovascularization and VEGF‐induced breakdown of the blood–retinal barrier , 2003 .
[3] M. Detmar,et al. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. , 2007, Blood.
[4] Claudio Campa,et al. Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.
[5] Satoshi Hirakawa,et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis , 2005, The Journal of experimental medicine.
[6] A. Adamis,et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. , 1998, Investigative ophthalmology & visual science.
[7] K. Red-Horse,et al. Endothelium-microenvironment interactions in the developing embryo and in the adult. , 2007, Developmental cell.
[8] B. Rouse,et al. Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis , 2001, Journal of Virology.
[9] F. Peale,et al. Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma , 2006, Clinical Cancer Research.
[10] R. Avery,et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[11] A. D. de Vos,et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.
[12] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[13] L. Damico,et al. DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[14] D. Hinton,et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.
[15] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[16] F. Peale,et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies , 2007, Proceedings of the National Academy of Sciences.
[17] J. Winer,et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. , 1992, Growth factors.
[18] F. Peale,et al. Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* , 2006, Journal of Biological Chemistry.
[19] Raymond M Schiffelers,et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. , 2004, The American journal of pathology.
[20] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[21] Mingde Zhu,et al. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. , 2006, Analytical biochemistry.
[22] I. Kasman,et al. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. , 2008, Investigative ophthalmology & visual science.
[23] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[24] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[25] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[26] Björn Bachmann,et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. , 2007, Investigative ophthalmology & visual science.
[27] R. Karlsson,et al. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. , 1997, Journal of immunological methods.
[28] D. Guyer,et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.
[29] P. Campochiaro,et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. , 2003, Journal of cellular physiology.